Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

ments to continue with Phase 1 clinical study of our proprietary product, TRU-016, as well as other product candidates."

2008 Financial Guidance

Trubion anticipates 2008 revenues to be in the range of $15 million to $20 million earned through the company's Wyeth collaboration. Total operating expenses are expected to be approximately $53 million to $58 million for 2008. The planned increase in 2008 operating expenses is primarily attributable to clinical trial expenses associated with the retreatment study being completed by Trubion for its lead product candidate, TRU-015, manufacturing and clinical costs associated with its TRU-016 product candidate, and increased personnel-related expense. Operating cash requirements in 2008 are expected to be approximately $35 million to $40 million.

Conference Call Details

Trubion will host a conference call and webcast to discuss its fourth-quarter and year-ended 2007 financial results and provide an update on business activities. The call will be held March 13 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website athttp://investors.trubion.com/events.cfm, or by calling 1 (877) 545-1491 or 1 (719) 325-4931. A replay of the discussion will be available beginning 8 p.m. Eastern Time from Trubion's website or by calling 1 (888) 203-1112 or 1 (719) 457-0820, and entering 7634379. The telephone replay will be available until midnight, Monday, March 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutic
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NY (PRWEB) July 26, 2014 ... Review, H2, 2014" provides data on the Ischemic ... report provides elemental information and data relating to ... Stroke. , View full global Ischemic Stroke Research ... includes an overview of the trial numbers and ...
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... April 11, 2012  Ikaria, Inc., a critical care ... for critically ill patients, today announced that Joseph ... In this role, Dr. Stauffer will be responsible ... regulatory activities related to Ikaria,s commercialized product, INOMAX® ...
... Advanced Biofuels, LLC, the biobutanol technology leader, commented ... patent infringement. (Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO ... for commercial production of isobutanol.  This is especially ... our ,188, ,889 and related patents filed by ...
... Systems Corporation has recently signed a strategic alliance ... Psyche,s award winning Anatomic Pathology solution, will be ... Lab, Siemens laboratory information system. ... is built on a contemporary architecture that is ...
Cached Biology Technology:Ikaria® Appoints Chief Medical Officer 2Ikaria® Appoints Chief Medical Officer 3Butamax™ Responds to Gevo Patent Infringement Lawsuit 2Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions 2
(Date:7/28/2014)... at Harvard University today announced that its human ... formed private company to accelerate development of pharmaceutical, ... The announcement follows a worldwide license agreement between ... start-up Emulate Inc., relating to the use of ... "This is a big win towards achieving our ...
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... the asteroid strike that wiped them out if it ... scientists say. , A fresh study using up-to-date fossil ... build a new narrative of the prehistoric creatures, demise, ... in the few million years before a 10km-wide asteroid ... upheaval. This included extensive volcanic activity, changing sea levels ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... May 4 TORONTO Greater levels of a brain protein ... and clinical depression are so common after childbirth according to an ... . Using an advanced brain imaging method, ... levels of brain MAO-A in healthy women four to six days ...
... French . , Explaining and understanding life ... Biologist Dr. Frdric Guichard is no exception in fact, ... reproduction and communication of mussels. Guichard says marine life ... fishery management and marine preservation practices. "If I kill mussels ...
... Dietetic Association has published an updated position paper on ... and their value, discusses barriers to participation and encourages ... helping children get and stay healthy. ADA,s updated ... Journal of the American Dietetic Association , represents ...
Cached Biology News:The bivalve effect 2ADA releases updated position paper on nutrition assistance programs for children 2
...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
... in this set of Antibody Microarray ... for a total of over 2100 ... internal control. Antibodies belonging to many ... cell cycle progression, signal transduction and ...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: